文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

儿童及青少年伯基特淋巴瘤/白血病一线BFM方案后进展或复发的结局分析

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy.
PubMed 文献 · Blood · 2020-01-01

该研究纳入1986至2016年间BFM协作组研究中一线治疗后进展的儿童伯基特淋巴瘤/白血病患者157例,3年生存率为18.5±3%。2000年后生存率从11±3%提升至27±5%(P<.001)。复发后进展时机、初始危险度及再诱导方案(含利妥昔单抗的连续输注化疗后移植)显著影响生存。

要点

  • 复发/进展后总体3年生存率仅18.5±3%,2000年后改善至27±5%。
  • 低危初治后复发者生存50±13%,高危方案后进展者仅21±5%。
  • 含利妥昔单抗连续输注再诱导后异基因移植生存67±12%。

核心结论

  • 当前有效一线治疗后复发的伯基特淋巴瘤/白血病儿童生存机会仍很差。
  • 初治或再诱导期间进展及初始高危疾病是复发后的风险因素。

研究设计与样本

  • 回顾性分析1986至2016年BFM协作组Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Münster研究中一线治疗后进展的儿童伯基特淋巴瘤/白血病157例。

主要发现

  • 157例患者3年生存率为18.5±3%。
  • 2000年前生存率11±3%,2000年后27±5%(P<.001)。
  • 低危(R1/R2)后复发14例生存50±13%,高危(R3/R4)后进展61例生存21±5%(P<.02)。
  • 一线治疗期间进展28例中25例死亡,再诱导期间进展32例中31例死亡。
  • 移植前未达完全缓解16例中15例死亡,再诱导未用利妥昔单抗13例全部死亡。

关键数值与推荐

  • 含利妥昔单抗连续输注化疗后异基因移植方案生存67±12%,其他方案及移植18±5%(P=.003)。

临床怎么用

  • 推荐再诱导方案包含利妥昔单抗及连续输注化疗,随后行异基因干细胞移植。
  • 对一线或再诱导期间进展、初始高危患者应尽早评估新药临床试验。

局限性

  • 2000年前患者未纳入风险因素分析。
  • 回顾性研究,治疗方案随年代变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with refractory or relapsed Burkitt lymphoma (BL) or Burkitt leukemia (B-AL) have a poor chance to survive. We describe characteristics, outcome, reinduction, and transplantation approaches and evaluate risk factors among children with progression of a BL/B-AL included in Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Münster studies between 1986 and 2016. Treatment recommendation was reinduction including rituximab from the early 2000s followed by blood stem cell transplantation. The 3-year survival of the 157 children was 18.5 ± 3%. Survival significantly improved from 11 ± 3% before to 27 ± 5% after 2000 (P < .001), allowing for risk factor analyses among the latter 75 patients. Survival of 14 patients with relapse after initial therapy for low-risk disease (R1/R2) was 50 ± 13% compared with 21 ± 5% for 61 patients progressing after R3/R4 therapy (P < .02). A total of 25 of 28 patients with progression during first-line therapy, 31 of 32 with progression during reinduction, 15 of 16 not reaching a complete remission (CR) before transplantation, 9 of 10 treated with rituximab front-line, and all 13 patients not receiving rituximab during reinduction died. Forty-six patients received stem cell transplantation (20 autologous, 26 allogeneic). Survival after a regimen combining rituximab with continuous-infusion chemotherapy followed by allogeneic transplantation was 67 ± 12% compared with 18 ± 5% for all other regimen and transplantations (P = .003). Patients with relapsed BL/B-AL have a poor chance to survive after current effective front-line therapies. Progression during initial or reinduction chemotherapy and initial high-risk disease are risk factors in relapse. Time-condensed continuous-infusion reinduction followed by stem cell transplantation forms the basis for testing new drugs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Woessmann W, Zimmermann M, Meinhardt A, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020. PMID: 31961927. doi:10.1182/blood.2019003591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。